A randomised trial of oral gammaglobulin in low-birth-weight infants infected with rotavirus

Abstract

Oral human gammaglobulin or placebo was given with each feed during the first week of life to 75 low-birth-weight babies. All were in a nursery where rotavirus was known to be endemic, 25 of the babies excreted rotavirus during the first 2 weeks of life. This group was regarded as the "challenge" group. Gammaglobulin administration was associated with delayed excretion of rotavirus and with milder symptoms of infection. Rotavirus-associated diarrhoea necessitating low-lactose feeds developed in 6 of 11 babies given placebo and 1 of 14 babies given gammaglobulin. Oral human gammaglobulin seems to protect low-birth-weight infants from diarrhoea caused by rotavirus.